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Background: The main control strategy for visceral leishmaniasis in Brazil has been based on the elimination of
seropositive dogs, although this is not widely accepted. In this context, the use of a long-lasting protective vaccine
against canine visceral leishmaniasis (CVL) has been highly expected. The aim of this work was to determine the
timeline kinetics of the cytokine microenvironment derived from circulating leukocytes as supportive immunological
biomarkers triggered by Leishmune® vaccine. Cross-sectional kinetic analysis of cellular immunity cytokines was
carried out at three times (1, 6 and 12 months) after primovaccination with Leishmune®. In vitro short-term whole
blood cultures were stimulated with Leishmania infantum soluble antigen (SLAg). The secreted cytokine signatures
and their major sources were determined.
Results: At six months after vaccination, Leishmune® induced an increase in IL-8, IFN-γ, IL-17a and TNF-α levels and
a decrease in IL-10. Cytokine signature analysis revealed a shift in the microenvironment towards a pro-
inflammatory profile mediated by IL-8 and IFN-γ. Both, CD4+ (↑TNF-α+ and ↑IFN-γ +) and CD8+ (↑IL-17a and ↓IL-4)
T-cells contributed to the acquired immune responses observed after stimulation with SLAg.
Conclusions: The changes observed in the cytokine profile suggested that Leishmune® was able to induce an
effective response at six months after primovaccination. After one year, it returned to baseline suggesting the
need of additional boosting.
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Visceral leishmaniasis (VL), caused by Leishmania infan-
tum (syn. Leishmania chagasi), is the most severe and
fatal form of leishmaniasis. Canine visceral leishmaniasis
(CVL) is a serious public health problem in the Americas,
Mediterranean region, Africa, Asia and Europe [1]. Dogs
are very susceptible to infection and the most important
domestic hosts [2,3]. Euthanasia of seropositive dogs is
recommended, but it did not effectively decrease the num-
ber of canine and human cases in Brazil [4]. Although
chemotherapy may reduce or eliminate clinical signs in* Correspondence: sobreira@cpqrr.fiocruz.br
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unless otherwise stated.sick dogs, parasitological cure is not achieved [5]. In fact, a
large proportion of infected dogs may become subclini-
cally infected after chemotherapy, but some of them can
still transmit the parasite to the sand fly vector. The use of
topical insecticides and impregnated collars, as well as
vaccines, is difficult to implement in a nationwide control
program [6]. In the absence of other successful strategies,
vaccine development against CVL has been quoted as one
more promising control measure [7]. There is a clear
consensus that CVL immunoprofilaxis may also have a
positive impact on the human leishmaniasis transmission.
However, although some available vaccines decrease infec-
tiousness of the disease for dogs, they still allowed sand fly
infection [8].entral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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the host immune response, persistence and multiplication
of the parasite. The innate and adaptive immunity compo-
nents are engaged in a wide range of complex interactions.
The initial steps in the innate immune compartment are
important for a successful development of an acquired im-
mune response [9,10]. Cytokines play a decisive role dur-
ing L. infantum infection [11]. Cellular immune responses
mediated by pro-inflammatory cytokines (IFN-γ and
TNF-α, were predominant in subclinically infected dogs,
suggesting their putative role for protection against the
disease. On the other hand, regulatory cytokines (IL-4 and
IL-10) seemed to be associated with disease progression
and severity [12]. However, there is a consensus that a
pro-inflammatory cellular immunity plays a relevant role
in the protective events during CVL [12-14].
Many efforts have been made by several groups in order
to develop a vaccine against CVL [15-17]. In Brazil, the
vaccine Leishmune® (Pfizer-Zoetis) was used for many
years. Nowadays, only one commercially available vaccine
is in use (Leish-Tec) (Hertape Calier). Leishmune® is com-
posed of a glycoproteic complex, fucose–mannose ligand
(FML), and Leish-Tec consists of the A2 recombinant
protein in saponin. Field studies in Brazil endemic areas
demonstrated that Leishmune® exhibited 76-80% efficacy
[18-20]. Leish-Tec was also a potent immunobiological
tool to prevent CVL, inducing high levels of IgG2 and
IFN-γ with concomitant decrease of IL-10 [21].
Here, the one-year timeline kinetics of the pro-
inflammatory and regulatory cytokines was evaluated in
Leishmune® vaccinated dogs. The cytokine profile pro-
duced by circulating leukocytes after short-term in vitro
stimulation with LSAg enabled the establishment of sup-
portive immunological biomarkers after primovaccination.
Methods
Ethics statement
The study protocol was approved by the Ethical Com-
mittee for the Use of Experimental Animals (CEUA) of
the Fundação Oswaldo Cruz (FIOCRUZ - PROTOCOL
No. P-71/11-3).
Dogs
In this work, 40 dogs of different breeds (18 males and 22
females), with ages ranging from 8 months to 8 years, were
selected in veterinary clinics located in Belo Horizonte,
Minas Gerais, Brazil and Informed written consent was ob-
tained from owners of all dogs. All dogs were evaluated
during the course of the experiments by their respective
Veterinary Doctors. Only healthy dogs from the same area
with negative serology (ELISA and Indirect Immuno-
fluorescence - IIF) for CVL and regular anti-helmintic
treatment were included in the study. Leishmune® primo-
vaccination was confirmed by immunization cards or inthe clinical record files at the veterinary clinics. This is a
cross-sectional study structured in three groups of 10 ani-
mals each, categorized according time after Leishmune®
primovaccination (T1, T6 and T12 stand for one, six and
twelve months post-vaccination, respectively). All dogs
had received subcutaneously the complete immunization
protocol proposed by the Leishmune® manufacturer
(Pfizer-Zoetis, Campinas, and São Paulo, Brazil). This
consisted of three shots with 21 days interval. A group
of ten seronegative non-vaccinated conscripts was in-
cluded as control (T0) to evaluate the pro and anti-
inflammatory basal levels of cytokines.
Leishmania infantum soluble antigen (SLAg)
Leishmania infantum promastigote forms (MHOM/BR/
1970/BH46) were grown in liver infusion tryptose
medium (LIT), supplemented with 10% of fetal bovine
serum at 24°C. SLAg production used stationary-phase
parasites (7 days of growth) as described [22]. Final pro-
tein concentration was adjusted to 1 mg/mL. Aliquots
were stored at -70°C prior to short-term in vitro
stimulation.
Short-term whole blood culture in vitro
Five mL of whole peripheral blood were collected from
each dog in heparinized vacuum tubes. In vitro short-
term cultures were performed as described by Silva et al.
[23] and whole blood leukocyte counts were determined
by automated hematology analyzer (Advia60, Bayer
Diagnostics, Tarrytown, NY, USA). Aliquots of 500 μL of
heparinized peripheral blood (containing 5-7×106 whole
blood leukocytes) were transferred to lithium heparin
Plasma Separator Tubes (Vacutainer® PST tubes, BD,
Franklin Lakes, NJ, USA) and incubated for 48 hours at
37°C, 5% CO2, in the presence of 475 μL of RPMI 1640
medium (GIBCO, Grand Island, NY). One tube, referred
as Ag-Stimulated Culture (SLAg), received 25 μL of L.
infantum soluble antigen (SLAg at 1 mg/mL, final con-
centration 25 μg/mL). A second tube, Control Culture
(CC), received 25 μL of RPMI. Finally, as internal posi-
tive control, was incubated with phorbol myristate acet-
ate (PMA; 25 ng/mL) and ionomycin (1 μg/mL) in
RPMI. The cultures were incubated at 5% CO2, 37°C for
48 hours.
Analysis of peripheral leukocyte secreted cytokines by
enzyme-linked immune sorbent assay (ELISA)
Following short-term whole blood culture in vitro, the
tubes were centrifuged 1,400 g for 10 minutes, and the
supernatant stored at -80°C in 100 μL aliquots for sol-
uble cytokines quantification by ELISA.
Soluble cytokine levels were determined by DuoSet
enzyme-linked immunosorbent assay (ELISA) to quantify
IL-8 (anti-canine IL-8, catalog number: DY1608); TNF-α
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number: DY1507); IFN-γ (anti-canine IFN-γ, catalog
number: DY781B) and IL-10 (anti-canine IL-10, catalog
number: DY735). Home-standardized ELISA was carried
out to quantify IL-4, using monoclonal anti-canine IL-4
antibody (catalog number: MAB7541) as capture antibody;
recombinant canine IL-4 (catalog number: 754CL) for
obtaining the standard curve and biotinylated anti-canine
IL-4 antibody (catalog number: BAF754), avidine peroxy-
dase (R&D Systems, DY998), and substrate solution (1:1
mixture of H2O2 and tetramethyl-benzidine, product code
50-76-4, lot. no. RB49).
Briefly, the ELISA assays were carried out by adding
25 μL of PBS-diluted monoclonal anti-cytokine to 96
well plates (COSTA®, Washington, DC, USA), followed
by overnight incubation at room temperature. After four
wash steps with PBS-Tween 20 buffer, blocking proce-
dures were carry out for 1 h with 0.1% of bovine serum
albumin (BSA) and 0.05% sodium azide in PBS. Follow-
ing four wash steps with PBS-Tween 20 buffer, 25 μL of
culture supernatant were added to specific wells. Along-
side, 25 μL of serial diluted recombinant cytokine were
used to establish the standard curve. The plates were in-
cubated for 2 h at room temperature, washed twice with
PBS-Tween 20 and 25 μL of biotinylated anti-cytokine
antibody were added to each well. After two wash steps
with PBS-Tween 20, 25 μL of avidine peroxydase diluted
in PBS – 0.1%BSA were added to each well and incu-
bated for 30 min at room temperature. After washing
steps with PBS, 25 μL of substrate solution (H2O2 and
tetramethylbenzidine, 1:1) were added and after 10 minutes
25 μL of stopping solution (H2SO4, 1 M) used as a final re-
agent. The optical density was determined by automatic
Absorbance Microplate Reader (Biotek, EL800, Winosski,
VT) at a wavelength of 450 nm. Minimum sensitivity of
ELISA were IL-8 (15.6 pg/mL), TNF-α 15.6 pg/mL), IFN-γ
(31.2 pg/mL) and IL-10 (31.2 pg/mL) as provided by the
manufacturer.
Immunophenotypic and intracytoplasmic cytokine staining
After short-term whole blood culture in vitro, 10 μL of
Brefeldin A (BFA; Sigma Chemical Company, St. Louis,
MO) at 1 mg/mL was added to each tube and cultures
were submitted to an additional incubation for four hours
at 5% CO2, 37°C. Then, 200 μL of ethylene diamine tetra
acetic acid – EDTA (Sigma, St Louis, USA) were added to
each culture tube (2 mM final concentration). After 10 mi-
nutes of incubation at room temperature, cultured whole
blood samples were washed with PBS supplemented with
0.5% bovine serum albumin and 0.1% sodium azide
(Sigma, St. Louis, USA). The cells were resuspended in
500 μL of PBS-0.5% BSA. Aliquots of 100 μL were stained
with anti-cell surface monoclonal antibodies (anti-CD4-
FITC and anti-CD8-A647, Table 1) for 30 minutes atroom temperature. After membrane staining, erythrocyte
lysis, and leukocytes fixation, the cell suspension was
permeabilized with PBS-0.05% BSA buffer supplemented
with 0.5% saponin. Aliquots of 50 μL were incubated in
the presence of phycoerythrin fluorochrome (PE)-labeled
anti-cytokines mAbs (IL-17a, TNF-α, IFN-γ, TGF-β and
IL-4 - Table 1), for 30 minutes at room temperature, in
the dark. After intracytoplasmic cytokine staining, the leu-
cocytes were washed with PBS-0.05% BSA and fixed in
FACS fixing solution (10 g/L paraformaldehyde, 10.2 g/L
sodium cacodylate, and 6.63 g/L sodium chloride, pH 7.2).
Flow cytometric measurements were performed on a
FACScalibur instrument (Becton Dickson - BD, USA)
interfaced to an apple G3 FACStation. The Cell-Quest™
software package provided by the manufacturer (Franklin
Lakes, NJ, USA) was used for data acquisition and analysis.
A total of 30,000 events were acquired for each prepar-
ation. The frequency of CD4+ and CD8+ T-cells expressing
intracytoplasmic cytokines (IL-17a, TNF-α, IFN-γ, TGF-β
and IL-4) was determined following the conventional strat-
egy analysis. This analysis consisted of selecting the popu-
lation of interest, based in morphometric aspects, through
punctual distribution of size (forward scatter- FSC) and
granularity (side scatter - SSC) graphs. After the selection
of the interest region R1 containing FSCLow SSCLow pheno-
type cells, graphs of density plot distribution of CD4/FL1
or CD8/FL4 versus IL-17a/FL2, TNF-α/FL2, IFN-γ/FL2,
TGF-β/FL2 or IL-4/FL2 were made to determine the per-
centage of IL-17a+, TNF-α+, IFN-γ+, TGF-β+ and IL-4+
cells inside the previously selected lymphocytes (Figure 1).
Final data was expressed as cytokine indexes, calculated by
dividing the percentage of cytokine positive cells observed
in the SLAg-stimulated culture by the one observed in
paired control unstimulated culture (SLAg/CC ratio).
Comparative data analysis
Conventional statistical analysis
The statistical analysis was performed using the software
GraphPad Prism 5.03. For the data presenting a para-
metric distribution, for example, intracytoplasmatic cy-
tokines, variance analysis (ANOVA) was used, followed
by Tukey test. For the non-parametric distribution, for
example, secreted cytokines in the supernatant, it was
performed the Kruskal-Wallis test, followed by Dunns
test. Differences were considered significant at p ≤ 0.05.
Comparative analysis of cytokines signatures secreted by
peripheral leucocytes
Cytokine signatures were compared to characterize the
pattern of secreted cytokines from each animal vacci-
nated as suggested [23,24]. Briefly, the “global median”
value for each secreted cytokine was calculated by taking
the whole universe of data (T0 + T1 + T6 + T12). The
“global median” was used as the cut off to tag each dog
Table 1 Monoclonal antibodies used for immunophenotyping assays intracytoplasmic detection of cytokines in vitro
Marker Host Clone Fluorochrome Manufacturer
Canine Anti-CD4 Rat YKIX302.9 FITC Serotec
Canine Anti-CD8 Rat YCATE55.9 A647 Serotec
Human Anti-IL17-a mouse 64DEC17 R-PE BD Pharmingen
Human Anti-TNF-α mouse MAb11 R-PE BD Pharmingen
Bovine Anti-IFN-γ mouse CC302 R-PE Serotec
Human Anti-TGF-β mouse TB21 R-PE IQ Products
Bovine Anti-IL 4 mouse CC303 R-PE Serotec
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kines in the culture supernatant as follows: (IL-8 =
2,087 pg/mL; TNF-α = 761 pg/mL; IFN-γ = 929 pg/mL;
IL-4 = 57 pg/mL and IL-10 = 135 pg/mL) (Figure 2A).
Following the assembling of dogs categorized as “Low”
or “High” cytokines producers, the frequency wasA
B
C
Figure 1 Representative dot plots illustrating the analysis of intracellular cy
short-term in vitro cultured (control or SLA-Ag stimulated) canine whole bloo
(Side scatter- SSC) used for lymphocyte gate selection (R1) of FSCLowSSCLow e
TGF-β and IL-4) CD4+ cells within gated lymphocytes and (C) Pseudocolor plo
within gated lymphocytes. The frequency of cytokines+ T-cells subsets were c
of gated lymphocytes prior to the calculation of the SLAg/Control indexes.calculated using gray-scale diagrams for each timeline
(T0, T1, T6 and T12) (Figure 2B). The ascendant fre-
quency of high cytokine for each timeline was assessed
to generate the T0, T1, T6 and T12 cytokine signatures
(bar charts) (Figure 2C). Relevant frequencies of “high
cytokine producers” were considered when thetokine profile in T-cell subsets. (A) Pseudocolor plot distribution of
d sample according to cell size (Forward scatter - FSC) and granularity
vents. (B) Pseudocolor plots representing cytokines + (IL-17, TNF-α, IFN-γ,
ts representing cytokines + (IL-17, TNF-α, IFN-γ, TGF-β and IL-4) CD8+ cells
alculated by quadrant statistics approach and first reported as percentage
Figure 2 (See legend on next page.)
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Figure 2 Signature analysis of secreted cytokine by peripheral blood leukocytes afterin vitrostimulation withLeishmania infantum soluble antigens
(SLAg). (A) Establishment of the global median cut-off edges for each cytokine (IL-8, TNF-α, IFN-γ, IL-4 and IL-10) used to segregate dogs as they
present “Low” ( ) or “High” ( ) cytokine levels. (B) Gray-scale diagrams used to compile the frequency (%) of high cytokine producers.
(C) Ascendant cytokine signatures were assembled for each time after vaccination (T0, T1, T6 and T12). The frequencies of high producers were
considered relevant (*) when the percentage was confined over the 50th percentile (doted lines). (D) Comparative analysis of cytokine signatures
were used to identify relevant differences amongst Leishmune® vaccinated dogs at one (T1 = black rectangle), six (T6 = dark grey rectangle) and
twelve (T12 = light grey rectangle) months post-vaccination compared to unvaccinated dogs (T0 = white rectangle). Gray scale rectangles were
used to highlight the shift in the overall profile of pro-inflammatory and regulatory cytokines on each time after immunization. Relevant differences
(shift of frequencies across the 50th percentile cut-off edge) were highlighted by gray background.
Costa-Pereira et al. BMC Veterinary Research  (2015) 11:92 Page 6 of 10percentage was above the 50th percentile. In a final step,
the cytokine signatures were converted from the bar
chart to line curves for overlaid comparative analysis
amongst each timeline (T0, T1, T6 and T12). Relevant
differences (shift of frequencies across the 50th percentile
cut-off edge) were highlighted by gray background
































Figure 3 Profile of cytokines secreted by peripheral blood leukocytes after
Short-term whole blood cultures were performed to characterize the cytokine
dogs at one (T1 = black rectangle), six (T6 = dark grey rectangle) and twelve (
unvaccinated dogs (T0 = white rectangle). Data are reported as cytokine leve
as median values over scattering distribution of cytokine levels. Significant difResults
Timeline kinetics of cytokines secreted by peripheral
blood leukocytes after in vitro stimulation
After stimulation with SLAg, a peak of leukocyte-secreted
pro-inflammatory cytokines (IL-8 an IFN-γ) was observed
at T6. This was concomitant with a decrease of IL-10











in vitrostimulation withLeishmania infantum soluble antigens (SLAg).
profile secreted by circulating leukocytes from Leishmune® vaccinated
T12 = light grey rectangle) months post-vaccination compared to
ls in culture supernatants in picograms/mL (pg/mL). Results are expressed
ferences at p ≤ 0.05 are highlighted by connecting line.
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importantly, IFN-γ, a relevant immunological biomarker,
was significantly increased at T1, re-enforcing the ability
of Leishmune® to trigger a protection pattern in primovac-
cinees. As expected, there is some basal production of
cytokines by the dogs at T0 (Figure 3).
Cytokine signature analysis further demonstrated that
Leishmune® vaccination shifted the immune response
towards a pro-inflammatory profile
After cytokine signature analysis (Figure 2), the frequency
of high producers was determined for each experimental
group of animals. This qualitative data re-emphasized the
supportive immune protection biomarkers observed after
Leishmune® vaccination. A shift towards pro-inflammatory
cytokines (IFN-γ and IL-8) was observed from T0 to T1
and sustained at T6. Concomitant decrease of regulatoryFigure 4 Intracytoplasmic cytokine indexes in peripheral blood leukocytes
(SLAg). Cytokine indexes were calculated as the proportion of cytokine+ ce
(SLAg/CC ratio) for Leishmune® vaccinated dogs at one (T1 = black rectangle), s
post-vaccination as compared to unvaccinated dogs (T0 = white rectangle). Da
(A) T-cells (B) CD4+ T-cells (C) CD8+ T-cells. Results are expressed as mean value
are highlighted by connecting line.cytokines (IL-4 and IL-10) was also observed at T1 and T6
compared to T0. Moreover, it was important to notice that
at T12, the cytokine signatures returned to baseline profile
similar to T0, with enhanced frequency of dogs presenting
high levels of IL-10 and IL-4.
Intracytoplasmic cytokine indexes in peripheral blood
leukocytes from Leishmune® vaccinated dogs after
in vitro stimulation with SLAg
In order to identify the major cytokine sources induced
in peripheral blood leukocytes after in vitro stimulation,
each dog cytokine indexes observed for T-cells and T-
cell subsets were calculated (Figure 4). A clear peak of
IL-17a, TNF-α derived from T-cells at T1 was observed
compared to other groups. Moreover, a decreased index
of IL-4 was observed at T6 compared to T1 (Figure 4A).
Analysis of CD4+ T-cells demonstrated a peak of TNF-αafterin vitrostimulation withLeishmania infantumsoluble antigens
lls observed in SLAg-stimulated cultures divided by the control culture
ix (T6 = dark grey rectangle) and twelve (T12 = light grey rectangle) months
ta are reported as cytokine indexes (SLAg/CC ratio) in lymphocytes
s of cytokine indexes ± standard error. Significant differences at p ≤ 0.05
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cytokine returned to baseline at T12 (Figure 4B). The
analysis of IFN-γ further demonstrated a peak at T6
(Figure 4B). Analysis of CD8+ T-cells revealed a clear
peak of IL-17a at T1 compared to other groups and a
decrease in the IL-4 index at T6 compared to T1 and T0
(Figure 4C). Together, these findings showed that T-
cells, both CD4+ and CD8+ subsets are relevant sources
of pro-inflammatory cytokines demonstrating the ability
of Leishmune® to trigger a protective immunological pat-
tern in primovaccinees.Discussion
Previous reports have demonstrated the long lasting pro-
tection against CVL using Leishmune® in endemic areas
[19]. This investigation evaluated the kinetics of the pro-
inflammatory and regulatory cellular immune response
in Leishmune® vaccinated dogs in a period of one year.
The immunocompetent host is able activate innate
and acquired inflammatory mechanisms responsible for
disease protection. In dogs, the cellular immune responses
mediated by phagocytes and T-cells, primarily involving
pro-inflammatory mediators (TNF-α, IL-6, IL-12 and
IFN-γ) and toxic oxygen intermediates are relevant in this
context. On the other hand, an impaired cellular response
is consistent with susceptibility [14,25]. Here, we have
evaluated by a cross-sectional investigation, the cytokine
profile triggered by Leishmune®. The timeline kinetics of
major pro-inflammatory and regulatory cytokines was de-
termined over a one year period. The data observed would
provide supportive insights to the animal health author-
ities regarding the vaccination guidelines currently recom-
mended for the Leishmune® vaccine.
Our data demonstrated that a clear increase in IL-8 and
IFN-γ in the group of Leishmune® vaccinated dogs at
6 months post-vaccination. In fact, IFN-γ increased in the
first month after vaccination compared to non-vaccinated
dogs. However, the increase of IL-8 and IFN-γ did not last
after 12 months, showing similar levels to non-vaccinated
dogs. On the other hand, a decrease in IL-10 was observed
at six months after vaccination, returning to similar levels
of the non-vaccinated dogs at T12.IL-8 is essential for neu-
trophil activity during the early events of the immune re-
sponse against Leishmania [26]. In our previous studies we
have demonstrated that Leishmune® vaccination induced
an increase in IFN-γ production by CD4+ T-cells [22,27].
The increase of those two cytokines in vaccinated dogs is
consistent with the ability of Leishmune® to trigger an im-
mune response. In this context, they could be classified as
immuneprotection biomarkers, since they returned to
baseline at T12. The regulatory cytokine IL-10 is known to
modulate the pro-inflammatory immune response, inhibit-
ing macrophages and promoting intracellular infection. Itslow levels at T6 could support a pro-inflammatory im-
mune profile, enabling parasite elimination [28].
In this study, one innovative tool [23,24] was also used
to evaluate the cytokine profiles triggered by Leish-
mune®. Cytokine signature analysis revealed a shift in
the cytokine milieu after SLAg stimulation. Similar to
our previous observations, a shift towards a pro-
inflammatory profile, especially mediated by IL-8 and
IFN-γ was observed at T1 and T6. Also, signature ana-
lysis showed a clear decreased in those cytokines at T12
with a simultaneous increase in the frequency of regula-
tory cytokines, at similar levels to non-vaccinated dogs.
This qualitative approach also re-enforced the use of
some of those leukocyte secreted cytokines as supportive
immuneprotection biomarkers. Those may be useful to
follow vaccination protocols after SLAg stimulation.
Leishmania elimination by phagocytes is a crucial step
for infection control and several reports have demonstrated
that their effective and persistent activation are controlled
by cytokines derived from the adaptive immunity [29,30].
In this context, it is likely to hypothetize that the post vac-
cination memory mediated by adaptive immunity cells may
be important for an effective activity of the innate immune
mechanisms. It has been proposed that CD4+ T-cells play
a decisive role in this process through the production of
cytokines and effectors mechanisms [31]. Consistent with
those observations, the analysis of the intracytoplasmic
cytokine profiles in T-cell subsets supported these findings.
Leishmune® vaccinated dogs showed increased indexes of
IL-17a and TNF-α early (one month) after primovaccina-
tion. This is similar to previous studies showing that those
cytokines were related to a CVL resistance phenotype
[32,33]. The analysis of T-cell subpopulations further
demonstrated that CD4+ T-cells were relevant sources of
TNF-α and IFN-γ. At the same time, CD8+ T-cells were an
important source of IL-17a and responsible for IL-
4decrease. The latter is associated with a regulatory
response modulating the pro-inflammatory profile, inhibit-
ing macrophage activity and promoting intracellular infec-
tion [28]. Our results also showed an important increase of
IFN-γ in CD4+ T-cells after in vitro stimulation with SLAg.
These results were similar to those observed by L. infan-
tum infected macrophages from dogs immunized with the
vaccine LiESAp (constituted of purified excreted antigen of
L. infantum promastigotes plus muramyl dipeptide as adju-
vant). Additionally, their co-cultivation with total lympho-
cytes results in higher levels of IFN-γ [34,35]. However,
our data showed a clear contribution of both CD4+ and
CD8+ lymphocytes for the acquired immune responses
after stimulation with SLAg.
Conclusions
The data observed showed that Leishmune® was able to
trigger changes in the immune response profiles in
Costa-Pereira et al. BMC Veterinary Research  (2015) 11:92 Page 9 of 10vaccinated dogs especially after 6 months. Although it
provided relevant information regarding Leishmune®
potential and immunization time, one of the limitations
of this study relies on the genetic variability of the dogs.
Although they had different characteristics (sex, age and
breed), it was clearly demonstrated that Leishmune® vac-
cination was able to shift the immune response towards
a pro-inflammatory profile. However, this was important
to validate the vaccine status in the real context. The im-
portant finding that all biomarkers (IL-8, TNF-α, IFN-γ,
IL-17a, IL-4 and IL-10) returned to baseline after one
year post vaccination re-enforced the need of boosting
doses. Also, it suggests their putative use as immune
protection biomarkers for vaccines evaluation. The con-
tinuity of this and other studies may help to generate infor-
mation to understand the immune response mechanisms
during CVL immunoprophylaxis.
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